Compile Data Set for Download or QSAR
Report error Found 34 Enz. Inhib. hit(s) with all data for entry = 50010936
TargetIntegrin alpha-IIb/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100346((S)-2-(3,5-Dimethyl-isoxazole-4-sulfonylamino)-3-[...)
Affinity DataIC50: 1nMAssay Description:Inhibition of binding of fibrinogen to purified human GPIIb-IIIa in ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50092105(2-(3,5-Dimethyl-isoxazole-4-sulfonylamino)-5-oxo-5...)
Affinity DataIC50: 2nMAssay Description:Inhibition of binding of fibrinogen to purified human GPIIb-IIIa in ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100350((S)-5-Oxo-5-(9-pyridin-4-yl-3,9-diaza-spiro[5.5]un...)
Affinity DataIC50: 2nMAssay Description:Inhibition of binding of fibrinogen to purified human GPIIb-IIIa in ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100344((S)-2-Butoxycarbonylamino-5-oxo-5-(9-pyridin-4-yl-...)
Affinity DataIC50: 4nMAssay Description:Inhibition of binding of fibrinogen to purified human GPIIb-IIIa in ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100351((S)-2-Benzyloxycarbonylamino-5-oxo-5-(9-pyridin-4-...)
Affinity DataIC50: 7nMAssay Description:Inhibition of binding of fibrinogen to purified human GPIIb-IIIa in ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100347((S)-2-(Butane-1-sulfonylamino)-5-oxo-5-(9-pyridin-...)
Affinity DataIC50: 23nMAssay Description:Inhibition of binding of fibrinogen to purified human GPIIb-IIIa in ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100352(3-Oxo-3-[4-(9-pyridin-4-yl-3,9-diaza-spiro[5.5]und...)
Affinity DataIC50: 43nMAssay Description:Inhibition of binding of fibrinogen to purified human GPIIb-IIIa in ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100356(3-[9-(4-Carbamimidoyl-phenyl)-3,9-diaza-spiro[5.5]...)
Affinity DataIC50: 160nMAssay Description:Inhibition of binding of fibrinogen to purified human GPIIb-IIIa in ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100343(2-{1-[9-(4-pyridyl)-3,9-diazaspiro[5.5]undec-3-ylc...)
Affinity DataIC50: 210nMAssay Description:Inhibition of binding of fibrinogen to purified human GPIIb-IIIa in ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100353(5-Oxo-5-(9-pyridin-4-yl-3,9-diaza-spiro[5.5]undec-...)
Affinity DataIC50: 240nMAssay Description:Inhibition of binding of fibrinogen to purified human GPIIb-IIIa in ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100355(6-Oxo-6-(9-pyridin-4-yl-3,9-diaza-spiro[5.5]undec-...)
Affinity DataIC50: 260nMAssay Description:Inhibition of binding of fibrinogen to purified human GPIIb-IIIa in ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100342(7-Oxo-7-(9-pyridin-4-yl-3,9-diaza-spiro[5.5]undec-...)
Affinity DataIC50: 270nMAssay Description:Inhibition of binding of fibrinogen to purified human GPIIb-IIIa in ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100357(8-Oxo-8-(9-pyridin-4-yl-3,9-diaza-spiro[5.5]undec-...)
Affinity DataIC50: 1.16E+3nMAssay Description:Inhibition of binding of fibrinogen to purified human GPIIb-IIIa in ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100345(5-[9-(4-Carbamimidoyl-benzoyl)-3,9-diaza-spiro[5.5...)
Affinity DataIC50: 3.50E+3nMAssay Description:Inhibition of binding of fibrinogen to purified human GPIIb-IIIa in ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100349(3-[9-(4-Carbamimidoyl-benzoyl)-3,9-diaza-spiro[5.5...)
Affinity DataIC50: 9.70E+3nMAssay Description:Inhibition of binding of fibrinogen to purified human GPIIb-IIIa in ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100348(4-[9-(4-Carbamimidoyl-benzoyl)-3,9-diaza-spiro[5.5...)
Affinity DataIC50: 1.50E+4nMAssay Description:Inhibition of binding of fibrinogen to purified human GPIIb-IIIa in ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100349(3-[9-(4-Carbamimidoyl-benzoyl)-3,9-diaza-spiro[5.5...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100348(4-[9-(4-Carbamimidoyl-benzoyl)-3,9-diaza-spiro[5.5...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100355(6-Oxo-6-(9-pyridin-4-yl-3,9-diaza-spiro[5.5]undec-...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100354(6-[9-(4-Carbamimidoyl-benzoyl)-3,9-diaza-spiro[5.5...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100356(3-[9-(4-Carbamimidoyl-phenyl)-3,9-diaza-spiro[5.5]...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100350((S)-5-Oxo-5-(9-pyridin-4-yl-3,9-diaza-spiro[5.5]un...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100357(8-Oxo-8-(9-pyridin-4-yl-3,9-diaza-spiro[5.5]undec-...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100347((S)-2-(Butane-1-sulfonylamino)-5-oxo-5-(9-pyridin-...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100351((S)-2-Benzyloxycarbonylamino-5-oxo-5-(9-pyridin-4-...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100354(6-[9-(4-Carbamimidoyl-benzoyl)-3,9-diaza-spiro[5.5...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of binding of fibrinogen to purified human GPIIb-IIIa in ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100353(5-Oxo-5-(9-pyridin-4-yl-3,9-diaza-spiro[5.5]undec-...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100352(3-Oxo-3-[4-(9-pyridin-4-yl-3,9-diaza-spiro[5.5]und...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100344((S)-2-Butoxycarbonylamino-5-oxo-5-(9-pyridin-4-yl-...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100345(5-[9-(4-Carbamimidoyl-benzoyl)-3,9-diaza-spiro[5.5...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100343(2-{1-[9-(4-pyridyl)-3,9-diazaspiro[5.5]undec-3-ylc...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100346((S)-2-(3,5-Dimethyl-isoxazole-4-sulfonylamino)-3-[...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100342(7-Oxo-7-(9-pyridin-4-yl-3,9-diaza-spiro[5.5]undec-...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50092105(2-(3,5-Dimethyl-isoxazole-4-sulfonylamino)-5-oxo-5...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed